Cipla to Acquire Venus Remedies’ Elores to Strengthen its Critical Care Footprints in India

 Cipla to Acquire Venus Remedies’ Elores to Strengthen its Critical Care Footprints in India

Cipla to Acquire Venus Remedies’ Elores to Strengthen its Critical Care Footprints in India

Shots:

  • Cipla acquires Venus’ anti-infective products, Elores to robust its presence in Indian critical care space as a part of its agenda to contribute to the fight against Anti-Microbial Resistance (AMR)
  • The acquisition will underscore Cipla’s commitment to anti-microbial stewardship and strengthen its branded anti-infectives portfolio in India with the addition of Elores and its prior acquisition of Zemdtrim
  • Elores is a novel combination of Ceftriaxone, Sulbactam and Disodium EDTA indicated to treat life-threatening infectious diseases caused by gram-negative bacteria, preserving the efficacy of antibiotics utilizing ARBs

Click here to­ read full press release/ article | Ref: Cipla | Image: Dalaal Street Investment Journal

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post